Why did PFE stock drop? — 2026-11-17

Research session: 2026-11-17. Published: 2026-11-17T21:33:43.237106+00:00.

Final report

PFE — Pfizer, Inc. Common Stock

Session close: $28.47. Regular-session share volume: 24,595,503. Change from previous close: -1.35%.

Key developments

Pfizer closed its acquisition of Metsera, marking a re-entry into the obesity drug market focused on injectables. The deal gives Pfizer control of Metsera's portfolio of long-acting obesity drug candidates targeting chronic weight management, and management plans to use those programs to compete in the crowded anti-obesity segment. The article notes investors should weigh the acquisition against the company's wider risks.

Company news Pfizer (PFE) Re Enters Obesity Drugs With Metsera Acquisition

A market report on drug and gene delivery devices lists Pfizer among the companies cited as accelerating next-generation delivery platforms, a sector-level reference rather than a company-specific development.

Company news Drug and Gene Delivery Devices - Global Strategic Business Report 2026: Capitalize on 8.1% CAGR to Secure the $1.2 Billion Market by 2032 as AbbVie, Moderna, Pfizer and Novartis Accelerate

News sources

Company news Drug and Gene Delivery Devices - Global Strategic Business Report 2026: Capitalize on 8.1% CAGR to Secure the $1.2 Billion Market by 2032 as AbbVie, Moderna, Pfizer and Novartis Accelerate · Company news Pfizer (PFE) Re Enters Obesity Drugs With Metsera Acquisition

Full report for 2026-11-17